JNJ-440

Alios Biopharma Inc. · Phase 1 active Small molecule

At a glance

Generic name	JNJ-440
Also known as	JNJ-64530440 or ALS-003440
Sponsor	Alios Biopharma Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

JNJ-440 CI brief — competitive landscape report
JNJ-440 updates RSS · CI watch RSS
Alios Biopharma Inc. portfolio CI